Check-Cap Ltd. (CHEK)
USD 0.68
(-3.88%)
USD 0.68
(-3.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -24.75 Million USD | -691.94% |
| 2022 | -3.12 Million USD | 87.65% |
| 2021 | -25.31 Million USD | -246.08% |
| 2020 | -7.31 Million USD | -0.85% |
| 2019 | -7.25 Million USD | 15.4% |
| 2018 | -8.57 Million USD | -22.51% |
| 2017 | -6.99 Million USD | 39.88% |
| 2016 | -11.63 Million USD | -23.92% |
| 2015 | -9.39 Million USD | -773.67% |
| 2014 | -1.07 Million USD | 78.39% |
| 2013 | -4.97 Million USD | -8.55% |
| 2012 | -4.58 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -24.75 Million USD | -691.94% |
| 2023 Q2 | -2.17 Million USD | 85.97% |
| 2023 Q4 | -24.75 Million USD | -638.32% |
| 2023 Q1 | -15.47 Million USD | -395.11% |
| 2023 Q3 | -3.35 Million USD | -54.44% |
| 2022 Q2 | -10.63 Million USD | -5.38% |
| 2022 Q3 | -8.3 Million USD | 21.89% |
| 2022 Q4 | -3.12 Million USD | 62.37% |
| 2022 FY | -3.12 Million USD | 87.65% |
| 2022 Q1 | -10.09 Million USD | 60.13% |
| 2021 Q1 | -14.01 Million USD | -91.56% |
| 2021 FY | -25.31 Million USD | -246.08% |
| 2021 Q3 | -38.48 Million USD | -329.88% |
| 2021 Q4 | -25.31 Million USD | 34.23% |
| 2021 Q2 | -8.95 Million USD | 36.1% |
| 2020 FY | -7.31 Million USD | -0.85% |
| 2020 Q1 | -6.3 Million USD | 13.09% |
| 2020 Q2 | -8.06 Million USD | -27.95% |
| 2020 Q3 | -5.96 Million USD | 26.04% |
| 2020 Q4 | -7.31 Million USD | -22.62% |
| 2019 Q1 | -7.97 Million USD | 6.98% |
| 2019 FY | -7.25 Million USD | 15.4% |
| 2019 Q4 | -7.25 Million USD | -9.05% |
| 2019 Q3 | -6.65 Million USD | 15.74% |
| 2019 Q2 | -7.89 Million USD | 1.03% |
| 2018 Q4 | -8.57 Million USD | -1.03% |
| 2018 Q2 | -9.95 Million USD | -114.41% |
| 2018 Q1 | -4.64 Million USD | 33.63% |
| 2018 FY | -8.57 Million USD | -22.51% |
| 2018 Q3 | -8.48 Million USD | 14.78% |
| 2017 FY | -6.99 Million USD | 39.88% |
| 2017 Q2 | -9.15 Million USD | 2.43% |
| 2017 Q3 | -6.94 Million USD | 24.17% |
| 2017 Q1 | -9.38 Million USD | 19.41% |
| 2017 Q4 | -6.99 Million USD | -0.82% |
| 2016 Q2 | -8.43 Million USD | 3.1% |
| 2016 FY | -11.63 Million USD | -23.92% |
| 2016 Q4 | -11.63 Million USD | -1.6% |
| 2016 Q3 | -11.45 Million USD | -35.78% |
| 2016 Q1 | -8.7 Million USD | 7.29% |
| 2015 Q2 | -19.08 Million USD | 3.82% |
| 2015 Q1 | -19.84 Million USD | -1745.58% |
| 2015 FY | -9.39 Million USD | -773.67% |
| 2015 Q4 | -9.39 Million USD | 3.6% |
| 2015 Q3 | -9.74 Million USD | 48.94% |
| 2014 Q1 | 4.97 Million USD | 200.0% |
| 2014 FY | -1.07 Million USD | 78.39% |
| 2014 Q2 | -2.79 Million USD | -156.16% |
| 2014 Q4 | -1.07 Million USD | 0.0% |
| 2013 Q1 | 8.03 Million USD | 0.0% |
| 2013 FY | -4.97 Million USD | -8.55% |
| 2013 Q3 | -4.97 Million USD | 0.0% |
| 2013 Q4 | -4.97 Million USD | 0.0% |
| 2012 FY | -4.58 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 37.25% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -318.597% |
| Aspira Women's Health Inc. | -331 Thousand USD | -7379.154% |
| Biodesix, Inc. | 34.3 Million USD | 172.16% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -327.127% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -1891.744% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -1891.744% |
| Bionano Genomics, Inc. | 34.88 Million USD | 170.971% |
| CareDx, Inc | -47.97 Million USD | 48.399% |
| Castle Biosciences, Inc. | -83.53 Million USD | 70.363% |
| DarioHealth Corp. | -7.54 Million USD | -227.981% |
| Exact Sciences Corporation | 1.94 Billion USD | 101.27% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 70.017% |
| Guardant Health, Inc. | 220.22 Million USD | 111.241% |
| ICON Public Limited Company | 3.56 Billion USD | 100.695% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 105.012% |
| Illumina, Inc. | 1.21 Billion USD | 102.039% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -355.689% |
| iSpecimen Inc. | -2.14 Million USD | -1052.824% |
| Standard BioTools Inc. | 46.5 Million USD | 153.232% |
| MDxHealth SA | 18.88 Million USD | 231.088% |
| 23andMe Holding Co. | -141.37 Million USD | 82.489% |
| Medpace Holdings, Inc. | -103.32 Million USD | 76.041% |
| Myriad Genetics, Inc. | 88.1 Million USD | 128.1% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 7176.074% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -914.796% |
| NeoGenomics, Inc. | 269.19 Million USD | 109.196% |
| Neogen Corporation | 735.62 Million USD | 103.365% |
| Inotiv, Inc. | 382.14 Million USD | 106.478% |
| Natera, Inc. | -200.1 Million USD | 87.628% |
| OpGen, Inc. | 11.89 Million USD | 308.176% |
| OPKO Health, Inc. | 230.68 Million USD | 110.732% |
| Psychemedics Corporation | 334 Thousand USD | 7511.976% |
| Prenetics Global Limited | -43.33 Million USD | 42.876% |
| Prenetics Global Limited | -43.33 Million USD | 42.876% |
| Precipio, Inc. | -386 Thousand USD | -6313.472% |
| Personalis, Inc. | -8.02 Million USD | -208.601% |
| RadNet, Inc. | 1.14 Billion USD | 102.155% |
| Sera Prognostics, Inc. | -2.02 Million USD | -1124.332% |
| Sotera Health Company | 2.02 Billion USD | 101.222% |
| Neuronetics, Inc. | 2.79 Million USD | 985.091% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -61.414% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -61.414% |
| Trinity Biotech plc | 63.73 Million USD | 138.841% |
| T2 Biosystems, Inc. | 33.8 Million USD | 173.223% |
| Twist Bioscience Corporation | -192.4 Million USD | 87.133% |
| Exagen Inc. | -12.77 Million USD | -93.83% |